Literature DB >> 29067721

The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.

Yasuo Sugita1, Takuya Furuta1, Koichi Ohshima1, Satoru Komaki1,2, Junko Miyoshi1,2, Motohiro Morioka2, Hideyuki Abe3, Takanori Nozawa4,5, Yukihiko Fujii4, Hitoshi Takahashi5, Akiyoshi Kakita5.   

Abstract

It has been shown that high expression of certain immune checkpoint molecules, including those of the programmed death protein 1/programmed death ligand 1 (PD-1/PD-L1) axis, can be utilized to regulate immunosuppression in the microenvironment of malignant neoplasms. For the purpose of clarifying the immune-escape mechanism of primary central nervous system lymphomas (PCNSLs), particularly in Epstein-Barr virus (EBV)-positive cases, markers for PD-1, PD-L1, tumor-associated macrophages (TAMs), and tumor-infiltrating lymphocytes (TILs) in 39 surgical specimens of PCNSLs (17 EBV-positive, 22 EBV-negative) were investigated by immunohistochemistry. Staining for PD-L1 was scored as follows: (-), no staining; (1+), 0-30% positive cells; (2+), 30-60% positive cells; and (3+), >60% positive cells. In EBV-positive cases, PD-L1 was detected in both lymphoma cells and TAMs in 12/17 cases, and in TAMs only in 4/17 cases. The mean number of PD-1, TIA-1 (a marker for cytotoxic T-cells), and FOXP3 (a marker for regulatory T-cells)-positive TILs in EBV-positive cases was 36.4 ± 45.9, 390 ± 603, and 9.88 ± 15.1, respectively. In EBV-negative cases, PD-L1 was detected in both lymphoma cells and TAMs in 11/22 cases, and in TAMs only in 4/22 cases. The mean of PD-1, TIA-1 and FOXP3-positive lymphocytes in EBV-negative cases was 67.3 ± 82.0, 158 ± 206 and 9.32 ± 17.5, respectively. We found no significant difference in the number of FOXP3-positive, lymphocytes between EBV-positive and negative cases. However, there were significantly higher numbers of PD-1-positive lymphocytes in the former, and significantly higher numbers of TIA-1-positive lymphocytes in the latter (P < 0.05). The combined data indicate that expression of PD-L1 by lymphoma cells and TAMs mediate the trafficking of TILs, which may explain the immune-escape process of PCNSLs. In addition, EBV infection appears to affect the trafficking mechanism of TILs, and may thus play an important role in the microenvironment immunity of these tumors.
© 2017 Japanese Society of Neuropathology.

Entities:  

Keywords:  Epstein-Barr virus; PD-1; PD-L1; immune escape; primary central nervous system lymphoma

Mesh:

Substances:

Year:  2017        PMID: 29067721     DOI: 10.1111/neup.12435

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  8 in total

1.  Insights in primary central nervous system lymphoma: a role for glymphatics?

Authors:  Ashwin Kumaria
Journal:  Brain Tumor Pathol       Date:  2021-09-17       Impact factor: 3.298

Review 2.  Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development.

Authors:  Kensuke Tateishi; Yohei Miyake; Taishi Nakamura; Tetsuya Yamamoto
Journal:  Brain Tumor Pathol       Date:  2021-07-13       Impact factor: 3.298

3.  Epstein-Barr virus-related diffuse large B-cell lymphoma in mogamulizumab-treated adult T-cell leukemia with incomplete T-cell reconstitution.

Authors:  Kazuharu Kamachi; Takero Shindo; Masaharu Miyahara; Kazutaka Kitaura; Michiaki Akashi; Tadasu Shin-I; Ryuji Suzuki; Koichi Oshima; Shinya Kimura
Journal:  Int J Hematol       Date:  2018-10-27       Impact factor: 2.319

4.  Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.

Authors:  Inju Cho; Hansang Lee; Sang Eun Yoon; Kyung Ju Ryu; Young Hyeh Ko; Won Seog Kim; Seok Jin Kim
Journal:  BMC Cancer       Date:  2020-02-13       Impact factor: 4.430

5.  Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients.

Authors:  Hirotaka Fudaba; Yasutomo Momii; Taisei Hirakawa; Kouhei Onishi; Daigo Asou; Wataru Matsushita; Yukari Kawasaki; Kenji Sugita; Minoru Fujiki
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

6.  The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling.

Authors:  Melissa Alame; Emmanuel Cornillot; Valère Cacheux; Valérie Rigau; Valérie Costes-Martineau; Vanessa Lacheretz-Szablewski; Jacques Colinge
Journal:  Theranostics       Date:  2021-01-22       Impact factor: 11.556

Review 7.  Epstein-Barr Virus and Neurological Diseases.

Authors:  Nan Zhang; Yuxin Zuo; Liping Jiang; Yu Peng; Xu Huang; Lielian Zuo
Journal:  Front Mol Biosci       Date:  2022-01-10

8.  PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.

Authors:  Motomasa Furuse; Hiroko Kuwabara; Naokado Ikeda; Yasuhiko Hattori; Tomotsugu Ichikawa; Naoki Kagawa; Kenichiro Kikuta; Sho Tamai; Mitsutoshi Nakada; Toshihiko Wakabayashi; Masahiko Wanibuchi; Toshihiko Kuroiwa; Yoshinobu Hirose; Shin-Ichi Miyatake
Journal:  BMC Cancer       Date:  2020-04-05       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.